OBJECTIVE: To compare incidence and distribution of non-AIDS-defining events (NADEs) among HIV-1-infected adults receiving combination antiretroviral therapy (cART) in urban sub-Saharan African versus United States settings. DESIGN: Retrospective cohort analysis of clinical trial and observational data. METHODS: Compared crude and standardized (to US cohort by age and sex) NADE rates from two urban adult HIV-infected cART-initiating populations: a clinical trial cohort in Gaborone, Botswana (Botswana) and an observational cohort in Nashville, Tennessee (USA). RESULTS: Crude NADE incidence rates were similar: 10.0 [95% confidence interval 6.3-15.9] per 1000 person-years in Botswana versus 12.4 [8.4-18.4] per 1000 person-years in the United States. However, after standardizing to an older, predominantly male US population, the overall NADE incidence rates were higher in Botswana [18.7 (8.3-33.1) per 1000 person-years]. Standardized rates differed most for cardiovascular events (8.4 versus 5.0 per 1000 person-years) and non-AIDS-defining malignancies (8.0 versus 0.5 per 1000 person-years) - both higher in Botswana. Conversely, hepatic NADE rates were higher in the United States (4.0 versus 0.0 per 1000 person-years), whereas renal NADE rates [3.0 per 1000 person-years (United States) versus 2.4 per 1000 person-years (Botswana)] were comparable. CONCLUSION: Crude NADE incidence rates were similar between cART-treated patients in a US observational cohort and a sub-Saharan African clinical trial. However, when standardized to the US cohort, overall NADE rates were higher in Botswana. NADEs appear to be a significant problem in our sub-Saharan African setting, and the monitoring, prevention, and treatment of NADEs should be a critical component of care in resource-limited settings.
OBJECTIVE: To compare incidence and distribution of non-AIDS-defining events (NADEs) among HIV-1-infected adults receiving combination antiretroviral therapy (cART) in urban sub-Saharan African versus United States settings. DESIGN: Retrospective cohort analysis of clinical trial and observational data. METHODS: Compared crude and standardized (to US cohort by age and sex) NADE rates from two urban adult HIV-infected cART-initiating populations: a clinical trial cohort in Gaborone, Botswana (Botswana) and an observational cohort in Nashville, Tennessee (USA). RESULTS: Crude NADE incidence rates were similar: 10.0 [95% confidence interval 6.3-15.9] per 1000 person-years in Botswana versus 12.4 [8.4-18.4] per 1000 person-years in the United States. However, after standardizing to an older, predominantly male US population, the overall NADE incidence rates were higher in Botswana [18.7 (8.3-33.1) per 1000 person-years]. Standardized rates differed most for cardiovascular events (8.4 versus 5.0 per 1000 person-years) and non-AIDS-defining malignancies (8.0 versus 0.5 per 1000 person-years) - both higher in Botswana. Conversely, hepatic NADE rates were higher in the United States (4.0 versus 0.0 per 1000 person-years), whereas renal NADE rates [3.0 per 1000 person-years (United States) versus 2.4 per 1000 person-years (Botswana)] were comparable. CONCLUSION: Crude NADE incidence rates were similar between cART-treated patients in a US observational cohort and a sub-Saharan African clinical trial. However, when standardized to the US cohort, overall NADE rates were higher in Botswana. NADEs appear to be a significant problem in our sub-Saharan African setting, and the monitoring, prevention, and treatment of NADEs should be a critical component of care in resource-limited settings.
Authors: Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: C William Wester; Hermann Bussmann; Sikhulile Moyo; Ava Avalos; Tendani Gaolathe; Ndwapi Ndwapi; Max Essex; Rob Roy MacGregor; Richard G Marlink Journal: Clin Infect Dis Date: 2006-11-08 Impact factor: 9.079
Authors: Rochelle P Walensky; A David Paltiel; Elena Losina; Lauren M Mercincavage; Bruce R Schackman; Paul E Sax; Milton C Weinstein; Kenneth A Freedberg Journal: J Infect Dis Date: 2006-06-01 Impact factor: 5.226
Authors: Frank A Post; Lucy J Campbell; Lisa Hamzah; Lisa Collins; Rachael Jones; Rizwan Siwani; Leann Johnson; Martin Fisher; Stephen G Holt; Sanjay Bhagani; Andrew H Frankel; Edmund Wilkins; Jonathan G Ainsworth; Nick Larbalestier; Derek C Macallan; Debasish Banerjee; Guy Baily; Raj C Thuraisingham; Paul Donohoe; Bruce M Hendry; Rachel M Hilton; Simon G Edwards; Robert Hangartner; Alexander J Howie; John O Connolly; Philippa J Easterbrook Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: E Martínez; A Milinkovic; E Buira; E de Lazzari; A León; M Larrousse; M Loncá; M Laguno; J L Blanco; J Mallolas; F García; J M Miró; J M Gatell Journal: HIV Med Date: 2007-05 Impact factor: 3.180
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: Niels Obel; Henrik F Thomsen; Gitte Kronborg; Carsten S Larsen; Per R Hildebrandt; Henrik T Sørensen; Jan Gerstoft Journal: Clin Infect Dis Date: 2007-05-10 Impact factor: 9.079
Authors: Norbert Bräu; Rena K Fox; Peiying Xiao; Kristen Marks; Zeenat Naqvi; Lynn E Taylor; Anita Trikha; Morris Sherman; Mark S Sulkowski; Douglas T Dieterich; Michael O Rigsby; Teresa L Wright; Maria D Hernandez; Mamta K Jain; Gajendra K Khatri; Richard K Sterling; Maurizio Bonacini; Catherine A Martyn; Ayse Aytaman; Josep M Llovet; Sheldon T Brown; Edmund J Bini Journal: J Hepatol Date: 2007-07-19 Impact factor: 25.083
Authors: Michael J Vinikoor; Jessica Joseph; Jonas Mwale; Melissa A Marx; Fastone M Goma; Lloyd B Mulenga; Jeffrey S A Stringer; Joseph J Eron; Benjamin H Chi Journal: AIDS Res Hum Retroviruses Date: 2014-08-05 Impact factor: 2.205
Authors: Shuntai Zhou; Kelly Martin; Amanda Corbett; Sonia Napravnik; Joseph Eron; Ye Zhu; Bryan Casciere; Cindy Boulton; Brittany Loy; Shayna Smith; Amanda Woods; Margaret Murray; Laura Ramsdell; David A Wohl Journal: AIDS Patient Care STDS Date: 2014-06 Impact factor: 5.078
Authors: Jessica L Castilho; Cathy A Jenkins; Bryan E Shepherd; Sally S Bebawy; Megan Turner; Timothy R Sterling; Vlada V Melekhin Journal: J Womens Health (Larchmt) Date: 2015-03-09 Impact factor: 2.681
Authors: Beatriz Grinsztejn; Mina C Hosseinipour; Heather J Ribaudo; Susan Swindells; Joseph Eron; Ying Q Chen; Lei Wang; San-San Ou; Maija Anderson; Marybeth McCauley; Theresa Gamble; Nagalingeshwaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Marineide Gonçalves de Melo; Kenneth H Mayer; Susan H Eshleman; Estelle Piwowar-Manning; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Ian Sanne; Joel Gallant; Irving Hoffman; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Diane Havlir; Myron S Cohen Journal: Lancet Infect Dis Date: 2014-03-04 Impact factor: 25.071
Authors: Martin Hoenigl; Carlee B Moser; Nicholas Funderburg; Ronald Bosch; Amy Kantor; Yonglong Zhang; Jesper Eugen-Olsen; Malcolm Finkelman; Jochen Reiser; Alan Landay; Daniela Moisi; Michael M Lederman; Sara Gianella Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: S S Martinez; A Campa; H Bussmann; S Moyo; J Makhema; F G Huffman; O D Williams; M Essex; R Marlink; M K Baum Journal: Br J Nutr Date: 2016-04-18 Impact factor: 3.718
Authors: Bethan McDonald; Sikhulile Moyo; Lesego Gabaitiri; Simani Gaseitsiwe; Hermann Bussmann; John R Koethe; Rosemary Musonda; Joseph Makhema; Vladimir Novitsky; Richard G Marlink; C William Wester; Max Essex Journal: AIDS Res Hum Retroviruses Date: 2013-05-09 Impact factor: 2.205